Nivolumab versus chemotherapy in advanced esophageal squamous cell carcinoma (ESCC): The phase III ATTRACTION-3 study

Cho, B.C.; Kato, Ken; Takahashi, Masanobu; Okada, Morihito; Lin, Chen‐Yuan; Chin, K.; Kadowaki, Shigenori; Ahn, Myung‐Ju; Hamamoto, Yasuo; Doki, Yuichiro; Yen, Chueh-Chuan; Kubota, Yutaro; Kim, S.-B.; Hsu, Chiun; Holtved, Eva; Xynos, Ioannis; Kitagawa, Yuko

doi:10.1093/annonc/mdz394.028

Cited by 13 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, patients with EAC showed no survival benefit [ 96 ]. These results were in line with both, the Keynote-061 trial, where Pembrolizumab failed to show any effect in gastro-esophageal junction adenocarcinoma [ 97 ], and the Attraction-3 study, where Nivolumab, another anti-PD-1 antibody, significantly prolonged overall survival compared to chemotherapy in ESCC patients [ 98 ]. These large clinical trials show that in ESCC immune checkpoint blockade is a valuable treatment approach that is as a single-agent even superior to chemotherapy in a palliative setting, but in EAC these drugs still have to show efficacy.…”

Section: T-cells and Myeloid-derived Suppressor Cells Immunotherapysupporting

confidence: 75%

Tumor Microenvironment of Esophageal Cancer

Schiffmann

Plum

Fuchs

et al. 2021

Cancers

View full text Add to dashboard Cite

Esophageal cancer is among the top ten most deadly cancers worldwide with adenocarcinomas of the esophagus showing increasing incidences over the last years. The prognosis is determined by tumor stage at diagnosis and in locally advanced stages by response to (radio-)chemotherapy followed by radical surgery. Less than a third of patients with esophageal adenocarcinomas completely respond to neoadjuvant therapies which urgently asks for further strategies to improve these rates. Aiming at the tumor microenvironment with novel targeted therapies can be one strategy to achieve this goal. This review connects experimental, translational, and clinical findings on each component of the esophageal cancer tumor microenvironment involving tumor angiogenesis, tumor-infiltrating immune cells, such as macrophages, T-cells, myeloid-derived suppressor cells, and cancer-associated fibroblasts. The review evaluates the current state of already approved concepts and depicts novel potentially targetable pathways related to esophageal cancer tumor microenvironment.

show abstract

Section: T-cells and Myeloid-derived Suppressor Cells Immunotherapysupporting

confidence: 75%

Tumor Microenvironment of Esophageal Cancer

Schiffmann

Plum

Fuchs

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…ORR was 19% (95% CI: 14-26.0%) and mDOR was 6.9 months (95% CI: 5.4-11.1 months) in the nivolumab group (210 patients). Compared with chemotherapy group, the nivolumab group showed better mOS (10.9 vs. 8.4 months; HR = 0.77, 95% CI: 0.62-0.96; p = 0.02) (45). The mPFS didn't display a statistically significant difference (1.7 vs. 3.4 months; HR = 1.08, 95% CI: 0.87-1.34).…”

Section: Pd-1/pd-l1 Inhibitors Alone Nivolumabmentioning

confidence: 84%

The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer

Yang

Wang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Esophageal cancer (EC) is one of the most common cancers with poor survival in the world. Nowadays, a generous number of clinical trials are underway on the use of immunotherapy in EC patients, especially the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors. However, only a few patients could benefit from single-agent therapy. Others need combination therapies to enhance the response rate and survival. In this review, we focus on PD-1/PD-L1 inhibitors and its combination options in EC patients. We also summarized the potential predictive biomarkers for PD-1/PD-L1 inhibitors treatment.

show abstract

“…[ 6 , 7 ] Through traditional platinum-containing chemotherapy, the median OS time of LSCC patients is only 8 to 12 months. [ 8 , 31 ] Although antiangiogenic drugs can prolong the survival time of advanced LSCC patients, their serious side effects, including pulmonary hemorrhage and pulmonary embolism, are particularly prominent. [ 32 , 33 ] However, ICI therapy has broken the embarrassing situation of the treatment of advanced LSCC.…”

Section: Discussionmentioning

confidence: 99%

The effect of pretreatment BMI on the prognosis and serum immune cells in advanced LSCC patients who received ICI therapy

Wang¹,

Zhou²,

Chen³

et al. 2021

Medicine

View full text Add to dashboard Cite

This study aims to evaluate the prognosis and serum immune cells of patients with different pretreatment body mass index (BMI) values. The data of 61 newly diagnosed patients with advanced lung squamous cell carcinoma (LSCC) who received immune checkpoint inhibitors (ICIs) combined with chemotherapy were obtained from the database of Rizhao People's Hospital (Rizhao, Shandong). According to the cutoff value of BMI (23.2 kg/m2), 32 patients had a high BMI and the remaining 29 patients had a low BMI. The effects of different BMIs on the prognosis and serum immune cells of patients were analyzed. The median progression-free survival (PFS) times were 7.72 months in the high BMI group and 4.83 months in the low BMI group [adjusted hazard ratio (HR), 0.23; 95% confidence interval (CI), 0.11–0.48; P < .001]. In terms of the overall survival (OS), the median times of the high BMI group and low BMI group were 18.10 and 13.90 months, respectively (adjusted HR, 0.15; 95% CI, 0.07–0.32; P < .001). After 4 cycles of ICI therapy combined with chemotherapy, the objective response rate was 59.4% for the high BMI group and 20.7% for the low BMI group (P = .002). In addition, the number of serum immune cells in patients with high BMI was significantly higher than that in patients with low BMI (all P < .001). There was a linear relationship between BMI value and the number of serum immune cells (all R 2 > 0.7). The current results showed that high BMI is associated with better prognosis in LSCC patients who received ICIs, which may be related to higher levels of serum immune cells.

show abstract

Nivolumab versus chemotherapy in advanced esophageal squamous cell carcinoma (ESCC): The phase III ATTRACTION-3 study

Cited by 13 publications

References 0 publications

Tumor Microenvironment of Esophageal Cancer

Tumor Microenvironment of Esophageal Cancer

The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer

The effect of pretreatment BMI on the prognosis and serum immune cells in advanced LSCC patients who received ICI therapy

Contact Info

Product

Resources

About